Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. · 2009

Read Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. by Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2654153.txt.

Introduction

Merabishvili and co-authors described in 2009 how they made a small batch of bacteria-killing viruses, called bacteriophages, pure enough to test in burn patients. Phages infect and burst specific bacteria. The mix aimed at two germs that often infect burns, Pseudomonas aeruginosa and Staphylococcus aureus, in a Brussels military hospital.

From a starting pool of 90 phages, three rounds of selection left just three winners. The team grew them, stripped out bacterial toxins, and ran strict checks: shelf life, sterility, heat-causing impurities, and safety on human cells. Gene and protein scans confirmed the phages kill rather than hide inside their hosts, and carry no toxin genes. Electron microscope images showed the right virus shapes attacking the right bacteria. A pilot trial in patients was already cleared to begin.

Catalog record

CREATORMerabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2654153

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials By Maya Merabishvili, Jean-Paul Pirnay, Gilbert Verbeken, Nina Chanishvili, Marina Tediashvili, Nino Lashkhi, Thea Glonti, Victor Krylov, Jan Mast, Luc Van Parys, Rob Lavigne, Guido Volckaert Published in: PLoS ONE DOI: 10.1371/journal.pone.0004944 ABSTRACT Abstract We describe the small-scale, laboratory-based, production and quality control of a cocktail, consisting of exclusively lytic bacteriophages, designed for the treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections in burn wound patients. Based on succesive selection rounds three bacteriophages were retained from an initial pool of 82 P. aeruginosa and 8 S. aureus bacteriophages, specific for prevalent P. aeruginosa and S. aureus strains in the Burn Centre of the Queen Astrid Military Hospital in Brussels, Belgium. This cocktail, consisting of P. aeruginosa phages 14/1 (Myoviridae) and PNM (Podoviridae) and S. aureus phage ISP (Myoviridae) was produced and purified of endotoxin. Quality control included Stability (shelf life), determination of pyrogenicity, sterility and cytotoxicity, confirmation of the absence of temperate bacteriophages and transmission electron microscopy-based confirmation of the presence of the expected virion morphologic particles as well as of their specific interaction with the target bacteria. Bacteriophage genome and proteome analysis confirmed the lytic nature of the bacteriophages, the absence of toxin-coding genes and showed that the selected phages 14/1, PNM and ISP are close relatives of respectively F8, φKMV and phage G1. The bacteriophage cocktail is currently being evaluated in a pilot clinical study cleared by a leading Medical Ethical Committee. INTRODUCTION In burn wound care, bacterial infection remains a major therapeutic problem and renders large numbers of thermal injuries virtually untreatable. Whereas Staphylococcus aureus remains a common cause of early burn wound infection, Pseudomonas aeruginosa is known as the most common and lethal infectious agent in burn centres, essentially due to its intrinsic and acquired resistance to antibiotics [1]–[3]. To improve burn wound patient care, research at the Laboratory for Molecular and Cellular Technology (LabMCT) of the Burn Centre of the Queen Astrid Military Hospital in Neder-over-Heembeek (Brussels), Belgium is investigating alternatives for the treatment of infections with multidrug resistant (MDR) infectious agents, like (bacterio)phage therapy. The use of bacteriophages against bacterial pathogens was first proposed by d'Hérelle in 1917 [4] and has a long and convoluted history. Currently, phage therapy is the subject of renewed interest, as a consequence of the continuing increase in antibiotic resistance worldwide [5], illustrated by the growing number of scientific papers and text books [6]–[12]. However, major obstacles for the clinical application of bacteriophages are the perception of viruses as ‘enemies of life’ [13], the lack of a specific frame for phage therapy in the current Medicinal Product Regulation [14] and the absence of well-defined and safe bacteriophage preparations. To evaluate the safety and efficacy of bacteriophages in the treatment of burn wound infections in a controlled clinical trial, we prepared a highly purified and fully defined bacteriophage cocktail (BFC-1), active against the P. aeruginosa and the S. aureus strains actually circulating in the Burn Centre of the Queen Astrid Military. To our knowledge the present paper describes for the first time, in detail - from the initial bacteriophage isolation to the final composition - a laboratory-based production of a well-defined bacteriophage cocktail. METHODS A flow chart of the entire BFC-1 production process and quality control tests is depicted in Figure 1 . [Figure: Flow chart of the BFC-1 production and final quality control.] Titration of bacteriophage suspensions using the agar overlay method The bacteriophage titre was determined by assaying decinormal serial dilutions (log(0) to log(−12)) of the bacteriophage suspensions with the agar overlay method [27], [28]. One ml of each dilution was mixed with 2.5 ml molten (45°C) Luria Bertani (LB) (Becton Dickinson, Erembodegem, Belgium), containing 0.7% top agar (Bacto agar, Becton Dickinson), and a suspension of bacteriophage sensitive bacteria (end concentration of 108 cfu/ml) in sterile 14 ml tubes (Falcon, Becton Dickinson). This mixture was plated in triplicate onto 90 mm diameter Petri dishes (Plastiques Gosselin, Menen, Belgium) filled with a bottom layer of 1.5% LB agar and incubated for 18–24 h at 37°C. To estimate the original bacteriophage concentration, plates with one to 100 distinguishable homogenous plaques were counted depending on the phage plaque size. The mean was then calculated for the triplicate plates. Initial isolation, separation and purification of P. aeruginosa and S. aureus lytic bacteriophages The bacteriophage sensitive strains used during the production and quality control of BFC-1 are P. aeruginosa strain ‘573’, were isolated at the Eliava Institute of Bacteriophage, Microbiology and Virology (EIBMV) in the 1970s from bone marrow interstitial fluid, and S. aureus strain '13 S44 S′, isolated at the Brussels Burn Centre in 2006 from a burn wound. Initially, S. aureus strain Wood 60 (EIBMV collection) was used for propagation of phage ISP, but for the production of this cocktail the phage was propagated on S. aureus 13 S44 S. The absence of temperate phages from the host strains was tested as described in a separate section of this paper. For bacteriophage isolation from natural samples such as sewage and river water, one millilitre of 10×concentrated LB Broth (Becton Dickinson), 1 ml ‘host bacteria’ suspension, containing 108 cfu in LB broth and 9 ml sewage or river water were mixed in a 14 ml sterile tube. This tube was incubated at 37°C for 1.5–2 h. Subsequently, 200 µl of chloroform (Sigma-Aldrich, Bornem, Belgium) was added and the tube was further incubated at 4°C for 1 h. The lysate was aspirated with a sterile 5 ml syringe and passed through a 0.45 µm membrane filter (Minisart, Sartorius, Vilvoorde, Belgium). Bacteriophages were titrated using the agar overlay method, as described above. All plaques with different morphology were touched with a sterile pipette tip, inoculated into 2 ml of sterile LB broth in 14 ml sterile tubes and incubated at 37°C for 2 h. Subsequently, 50 µl of chloroform was added and the tube(s) were incubated at 4°C for 1 h. For each tube, a dilution series (log(0)−log(−4)) was made in sterile 14 ml tubes filled with LB broth. Each dilution was titrated using the agar overlay method. Plates showing 1–10 plaques were analysed in detail. Again, all plaques with different morphology were touched with a sterile pipette tip, inoculated into 2 ml of sterile LB broth in 14 ml sterile tubes and incubated at 37°C for 2 h. This complete cycle was repeated until one plaque morphotype was obtained (homogeneous plaques). In the case of bacteriophage ISP, which was isolated in the 1920s, porcelain, rather than membrane filters were employed. Production of bacteriophage stocks Bacteriophage stocks were prepared using the double-agar overlay method with minor modifications. One millilitre of lysate (see above) containing 103–105 plaque forming units (pfu) of bacteriophages was mixed with 2.5 ml molten (45°C) Select Alternative Protein Source (APS) LB (Becton Dickinson, Erembodegem, Belgium) top agar (0.7%) and a bacteriophage sensitive bacterial suspension (end concentration of 108 cfu/ml) in a sterile 14 ml tube. This mixture was plated onto ten 90 mm diameter Petri dishes filled with a bottom layer of 1.5% APS LB agar and incubated at 37°C for 16–18 h. Subsequently, 200 µl of chloroform was added to the lids of the Petri dishes

Read the complete text